|Bid||130.55 x 800|
|Ask||140.99 x 900|
|Day's Range||128.26 - 132.88|
|52 Week Range||105.12 - 179.65|
|Beta (3Y Monthly)||4.01|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||179.09|
A health drink company called New Age Beverages is cashing in on the ongoing cannabis craze. Yahoo Finance’s Alexis Christoforous speaks to the CEO of New Age Beverages Brent Willis.
Cannabis is a hugely exciting market right now. Marijuana stocks are surging following multiple positive regulatory movements: Utah and Missouri voters both just passed resolutions to legalize medical cannabis, Michigan voted to green-light recreational marijuana and outspoken anti-cannabis Attorney General Jeff Sessions has now resigned. Meanwhile, Canada recently became the first major world economy to legalize cannabis for both medical and recreational use. It's not clear whether the U.S. will follow in our neighbor's footsteps. What is clear is that pro-marijuana legislation is spreading, and marijuana-friendly policies at least feel a little more likely with a Democratic majority in the U.S. House of Representatives. Bear in mind, 70% of Democrats support marijuana legalization vs just 45% of Republicans. Here are the top marijuana stocks to buy if you want to take advantage of these latest developments. We use TipRanks' market data to pinpoint four of the most promising marijuana stocks out there. As you will see, all four of these stocks have a consensus "Buy" rating from Wall Street's best minds. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET. Analysts expect Trulieve to report revenues of 35.1 million Canadian dollars for the third quarter of 2018. Trulieve is a vertically integrated cannabis company involved in the cultivation, production, and commercialization of cannabis products in the State of Florida.
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary in the Midtown area. The above chart lists the details about Curaleaf’s new dispensary in Tallahassee.
CBD, which is short for cannabidiol, is the second-most present ingredient in marijuana. Cannabidiol is one of more than 100 discovered components in marijuana that are commonly known as cannabinoids. The research into the benefits of CBD is fairly new, and the conditions and symptoms it can treat are still being discovered.
Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH ), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy ...
WeedMD (WMD) is a Canada-based licensed producer of medical marijuana. On November 13, the company announced that Health Canada approved its cannabis sales license for cannabis cultivated at its greenhouse in Ontario. The below chart lists some key highlights of WeedMD’s greenhouse. According to the company’s press release, the original license, which was issued under the Access to Cannabis for Medical Purposes regulations, was migrated to the license issued under the Cannabis Act regulations.
Leerink initiated coverage of GW Pharmaceuticals PLC ADR early Wednesday with an "outperform" rating and a price target of $185. GW Pharma develops medications that use cannabinoids, the chemical compounds in marijuana, and shares of the company closed at $132.18 on Tuesday. "We like new epilepsy drugs," Leerink analyst Marc Goodman said, predicting blockbuster sales of the company's lead product, Epidiolex, which has been approved in the U.S. for seizures associated with two rare types of childhood epilepsy. Goodman was also bullish on GW Pharma's second product, Sativex, which is intended for the muscle tightness and spasms that are symptoms of multiple sclerosis and has been approved in other countries, though not in the U.S. so far. The analyst said that Sativex "receives minimal attention" but could bring in global sales of $340 million by the end of 2030. "Epilepsy is a high operating margin business model, so our sales forecasts should drive strong bottom-line profits," Goodman said. "The company's deep cannabinoid science platform and proprietary know-how in this area should enable it to develop additional products to sustain growth." GW Pharma shares were not active in premarket trade. Shares have dropped nearly 4% month-to-date, compared with a 0.4% rise in the S&P 500 .
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. Analysts expect Curaleaf Holdings to report revenue of 31.4 million Canadian dollars in the third quarter.
HENDERSON, NV / ACCESSWIRE / November 13, 2018 / Last Tuesday's election was great news for cannabis companies. With Michigan approving recreational marijuana and several other measures passing investors ...
The wave of marijuana legalization in recent years has more and more Americans toking up legally and experimenting with everything from candy to skincare products infused with cannabis. CBD products have become increasingly popular in recent years, as more and more producers market CBD as the new "it" drug for the health and wellness set — one that has been touted as a pain reliever and a treatment for anxiety, among other potential applications. Last year, consumer sales of CBD products topped $350 million in the United states, more than triple the amount sold in 2014, and various estimates predict the market could reach $2 billion within the next two to four years .
GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.
Bank of Montreal owned $73 million in U.S.-listed pot stocks at the end of the third quarter. CIBC and U.S. Bancorp owned $5 million and $2 million, respectively.
Teva Pharmaceutical (NYSE:TEVA) is doing a lot better this year — up just shy of 20%. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat.
Amid all the ruckus of 2018 an investing thesis has emerged that has taken Wall Street by storm: Marijuana stocks surged almost like bitcoin did in its heyday.
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / As the stock market plummeted early October cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set ...
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its fourth quarter and year-end financial results for the period ending 30 September, 2018. GW will also host a conference call the same day at 4:30 p.m. EST. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $145.71, marking a -1.05% move from the previous day.
The global cannabis industry took two big steps forward this week. On Oct. 31, Mexico’s Supreme Court said the laws that ban recreational weed are unconstitutional, essentially opening the door for a potential legalization of pot in the future. The UK government rescheduled certain cannabis-based products for medicinal use.